In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
National regulators in Australia and the United Kingdom (UK) have issued safety advisories on the association between pioglitazone use and bladder cancer. The Australian advisory noted that males were at higher risk of bladder cancer than females, while the UK advisory highlighted a new recommendation, suggest careful consideration in the elderly due to increasing risk with age.
In an updated review in 2016, the U.S. Food and Drug Administration (FDA) concluded that use of pioglitazone may be linked to an increased risk of bladder cancer. The FDA advised that pioglitazone should not be used in patients with active bladder cancer, and should carefully consider the benefits and risks before using pioglitazone in patients with a history of bladder cancer.
Contra-indicated in patients with established NYHA Class III or IV heart failure.
CONGESTIVE HEART FAILURE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.